Drug intelligence / Profile preview

ChAdOx1-HBV + MVA-HBV + nivolumab

Development stage: Unknown
Lead developer: Barinthus Biotherapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular, Intravenous

Overview

ChAdOx1-HBV + MVA-HBV + nivolumab is a combination investigational regimen involving two therapeutic hepatitis B virus (HBV) vaccines and an immune checkpoint inhibitor. **ChAdOx1-HBV** is a chimpanzee adenovirus vector-based vaccine encoding major HBV antigens and a genetic adjuvant designed to induce strong T cell immunity against HBV, developed for chronic hepatitis B infection. **MVA-HBV** is a recombinant Modified Vaccinia Ankara virus expressing HBV antigens, used as a vaccine booster following priming with ChAdOx1-HBV to enhance the adaptive immune response. **Nivolumab** is an anti-PD-1 monoclonal antibody that blocks programmed cell death-1 (PD-1) receptor signaling, reactivating T cells and enhancing immune clearance of virus-infected cells. This triplet regimen aims to restore and amplify anti-HBV immune responses to achieve a functional cure in chronic hepatitis B, leveraging both active vaccination and immune checkpoint blockade.

Brand names: Opdivo
Other names: ChAdOx1-HBV + MVA-HBV + nivolumabVTP-300 plus nivolumabVTP300 plus nivolumabVTP 300 plus nivolumabVaccitech prime-boost HBV vaccine plus nivolumab

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on ChAdOx1-HBV + MVA-HBV + nivolumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ChAdOx1-HBV + MVA-HBV + nivolumab.

Explore the full profile